Journal article

Why should regulators consider using patient preferences in benefit-risk assessment?

JA Van Til, MJ IJzerman

Pharmacoeconomics | ADIS INT LTD | Published : 2014

DOI: 10.1007/s40273-013-0118-6

University of Melbourne Researchers

Grants

Citation metrics

38Scopus
37Web of Science
48Dimensions

Keywords

4203 Health Services and Systems
Consumers
3214 Pharmacology and Pharmaceutical Sciences
Life Sciences & Biomedicine
Conjoint-Analysis
Social Sciences
38 Economics
Business & Economics
3801 Applied Economics
Health Technology-Assessment
Health Care Sciences & Services
Perspective
Pharmacology & Pharmacy
Science & Technology
Care
32 Biomedical and Clinical Sciences
42 Health Sciences
Economics
Health Policy & Services
Outcomes